Brain diseases an outcome of cannibalism,,,,
The main cause of deadly brain-wasting diseases might be just what the... Pinpointing the selection pressureResearch on women who feasted...The protective mutations now appear in the DNA of people around th...
The main cause of deadly brain-wasting diseases might be just what the researchers have for long been prodding into - Cannibalism. Abnormal proteins called the prions resultantly cause a brain-wasting disease called Creutzfeld Jacob disease (CJD) and bovine spongiform encephalopathy, or mad cow disease in humans. The presence of this protein causes other proteins to be clumped together. CJD is usually found in large numbers// in people who take flesh with infectious prions. These as a result kill the brain cells. This disease is found in about one in a million people. A disease called kuru common among the Fore people in Papua New Guinea was mainly due to eating their deceased relatives in the mortuary feasts. There are genetic mutations called polymorphisms which resist the disease. Researchers have reported that natural selection appears to have spread through the population.
Pinpointing the selection pressure
Research on women who feasted on the deceased ones was carried out. It suggested that there is a certain genetic variation and mutation which is more prevalent in women over 50 than young women. Some women who feasted on the deceased ones and yet were living were tested by the researchers. Ample evidence suggests that the protective mutation through generations had protected them from disease. The mutation protects against CJD too. Mutations do protect from diseases, with evidences from pre-historic age. There is much skepticism about the fact that all the early human being were cannibals.
The protective mutations now appear in the DNA of people around the world. Other prion researchers want to verify the findings with data from larger population samples.
Since prions can cross between species, it is also possible that eating animals with prion diseases could have contributed to the spread of the protective gene. The protective mutations now appear in the DNA of people around the world. Other prion researchers want to verify the
'"/>Page: 1 2 Related medicine news :1.
Use of Cellular Phones associated with Increased risk of Brain Tumors2.
Brain death – How to cope with it3.
“Brain fingerprinting”- The new lie detectr4.
Nasal Spray Could Take Drugs Direct to Brain.5.
Virus Combats Brain Tumour6.
Nasal Spray Could Take Drugs Directly to Brain7.
Control of anger disorder connected to Brain Dysfunction8.
High Levels of Protein Linked to Brain Shrinkage 9.
Brain damage affects artistic skill10.
Brain cells protected by new compounds 11.
Brain changes observed in people with sleep apnoea
(Date:12/5/2008)...yzoom provides physicians and their office manager... Columbus, OH (PRWEB) Decemb...as launched Phase I of PHYZOOM, a suite of web-bas...icians, PHYZOOM offers numerous practice marketing...sician and practice profiles, easy to use blogging...
(Date:12/4/2008)...swire-USNewswire/ -- In the 1983 movie "A Christma...hat a Red Ryder BB gun is the perfect gift. , ... he got from his parents, teacher and even Santa C... quotes from this Christmas classic because we,ve ...unfortunately, it comes true for too many people. ...
(Date:12/4/2008)... people over a 20-year period suggests your smile ..., Dec. 4 (HealthDay News) -- Happy friends can mak...iends. , That,s the unusual conclusion of a new...et can have an impact on each other,s feelings. ,...le we,re directly connected to," said study co-aut...
(Date:12/4/2008)...re-USNewswire/ -- The U.S. Government, through the..., is providing an additional $600,000 to help comb...nce is in addition to the $4 million water, sanita...dy implementing in Zimbabwe. , , "Before ch...the international community to prepare for the pos...
Breaking Medicine News(10 mins):Health News:OnKua, Launches Phase I Of "Phyzoom" A Web-Based Physician Marketing And Customer Relationship Management Product 2Health News:OnKua, Launches Phase I Of "Phyzoom" A Web-Based Physician Marketing And Customer Relationship Management Product 3Health News:Texas Parents Can Prevent Holiday Tragedies with Safe Toys and Celebrations 2Health News:Being Happy Affects Even Those You Don't Know 2Health News:Being Happy Affects Even Those You Don't Know 3Health News:USAID Increases Assistance for Zimbabwe Cholera Outbreak 2...rd researchers suggests a link between the hepatit...study, people who received the vaccine were three-...hree years than those who were not vaccinated. Whi...tigators emphasize the overall effect of the vacci...
... an increased risk for life-threatening cardiovasc...etes would be well // advised to monitor their blo..., according to a new study. Researchers conducted ...ed observational studies focused on the relationsh...
...itis in asthma patients tends to be more severe an...hers suggest patients // can have dramatic improve...surgical options is used. In the study patients wi...cidence of nasal polyps, olfactory dysfunction, an...
... designed to educate parents about allergens and t...in children // say researchers .More than 900 ch... allergic to at least one indoor environmental all...earch shows children who live in these areas suffe...
Other Medicine News:(Date:12/4/2008)...nist to Advance to Clinical Trials , , SAN ...als, Inc., a biopharmaceutical company focused on ...8) agonists for the treatment of cancer, respirato...t has initiated a Phase I clinical trial of VTX-23...cancer. The multi-center clinical trial is being ...
(Date:12/3/2008)...a demonstrating potential in newly diagnosed patie... featured in two oral sessions at ASH , , -...cally transfused patients by significantly reducin... - New long-term data from major independent breas...surgery treatment strategy, Femara vs. tamoxifen ,...
(Date:12/3/2008)...lleviates long-term anemia and organ damage in mic..., MEMPHIS, Tenn., Dec. 3 /PRNewswire-USNewswire... gene into mouse blood cells, scientists at St. Ju...ckle cell disease pathology. In their studies, the...sentially no difference from normal mice. Although...
(Date:12/3/2008)...Newswire/ -- Isogen, a contract development and,m...ounced it has retained a,strategic financial part...l,biopharma demand for Isogen,s services. , ...st round series of capital,investment and the ope... to,deliver on the previously unmet process, faci...
Breaking Medicine Technology:VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 5More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 6More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 7More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 8More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 9More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 10More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 11More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 12More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 13More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 14More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 15More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 16More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 17More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 18More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 19More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 20More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 21More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 22Gene Therapy Corrects Sickle Cell Disease in Laboratory Study 2Gene Therapy Corrects Sickle Cell Disease in Laboratory Study 3Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand 2Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand 3Are Muramyl Peptides the Magic Bullet in Probiotics 3F 1038 1Are Muramyl Peptides the Magic Bullet in Probiotics 3F 1038 2Are Muramyl Peptides the Magic Bullet in Probiotics 3F 1038 3With Obesity Diabetes and Cardiovascular Disease on the Rise Physicians Need More Comprehensive Guidelines 8040 1With Obesity Diabetes and Cardiovascular Disease on the Rise Physicians Need More Comprehensive Guidelines 8040 2SGI Introduces the SGI BioCluster Life Sciences Workflow Solution 8037 1SGI Introduces the SGI BioCluster Life Sciences Workflow Solution 8037 2SGI Introduces the SGI BioCluster Life Sciences Workflow Solution 8037 3SGI Introduces the SGI BioCluster Life Sciences Workflow Solution 8037 4InterCure Names Scot Dube Vice President of Sales 8034 1InterCure Names Scot Dube Vice President of Sales 8034 2InterCure Names Scot Dube Vice President of Sales 8034 3...rgroupe Francophone du Myelome (IFM),Trial Present...PRNewswire-FirstCall/ --,Millennium Pharmaceutical...d on the comparative Phase III clinical trial eval...multiple myeloma (MM),patients. As induction thera...ELCADE based therapy produced a high complete remi...
...-- Ablynx today announced positive,interim results...pment programme, ALX-0081, an anti-thrombotic trea...cute; therapeutic,Nanobody® targeting von Will...thrombosis in patients with acute coronary,syndrom...signed to assess,safety, tolerability and pharmaco...
Other Medicine Technology:Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 2Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 3Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 4Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 5Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 6Ablynx Announces Interim Results of First Nanobody Phase I Study of,ALX-0081 (ANTI-VWF) 2Soft PVC. Available in sizes 12-36F, Interior striations for smooth suction catheter insertion. Bevel tip. Single use. Sterile.
Smooth flexible medical grade white low density polyethylene with reinforced block to prevent collapse.
All oral and nasal airways are manufactured with smooth, rounded edges for increased patient comfort and safety., ,Portex® offers a broad selection of airways for a variety of clinical applicati
Black elastomer. Smooth finish. Non-Sterile.
Medicine Products: